NEW YORK (TheStreet) -- Mylan (MYL) rose Friday after the pharmaceutical company increased its all-stock offer for Swedish rival Meda to $9 billion. Meda previously rejected a takeover offer earlier this month. The company subsequently said it had been contacted with a proposal to combine the two companies, but Meda's board rejected this, too. The stock was up 2.01% to $51.36 at noon on Friday. SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more. MYL data by YCharts STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.